Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
08 août 2024 06h30 HE
|
Veru Inc.
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected...
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
01 août 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru to Participate in the BTIG Virtual Biotechnology Conference
29 juil. 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
02 juil. 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
24 juin 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
18 juin 2024 16h05 HE
|
Veru Inc.
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
17 juin 2024 16h45 HE
|
Veru Inc.
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
10 juin 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru to Present at the Jefferies Global Healthcare Conference
22 mai 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
15 mai 2024 08h30 HE
|
Veru Inc.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...